Completed PHASE4 INTERVENTIONAL NCT00319670

A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children

Sponsor: Braintree Laboratories

Interventions MiraLax

Updated 5 times since 2017 Last updated: Feb 6, 2013 Started: Mar 31, 2006 Primary completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00319670, this PHASE4 trial focuses on Constipation and remains completed. Sponsored by Braintree Laboratories, it has been updated 5 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Braintree Laboratories

Data source: Braintree Laboratories

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Youngstown, United States